08:00 , Dec 22, 2003 |  BC Week In Review  |  Company News

Avant, Biosidus biomanufacturing news

The companies settled an arbitration proceeding concerning a 2001 manufacturing deal. In June, AVAN discontinued the deal with Biosidus for AVAN's CholeraGarde vaccine to prevent cholera infection and initiated arbitration to resolve contractual issues between...
07:00 , Jun 23, 2003 |  BC Week In Review  |  Company News

Avant, Biosidus, Walter Reed deal

AVAN discontinued a manufacturing deal with Bioaidus for AVAN’s CholeraGarde vaccine to prevent cholera infection. As part of the termination, AVAN also said it began arbitration proceedings in the State of New York to reconcile...
08:00 , Feb 25, 2002 |  BC Week In Review  |  Company News

Avant, International Vaccine Institute deal

AVAN will donate its Peru-15 cholera vaccine to the institute, which will run clinical trials of the product in Bangledesh. Phase IIb data for the product were reported last year and showed 100% protection against...
07:00 , May 14, 2001 |  BC Week In Review  |  Company News

Avant, Biosidus, Prodigene deal

Biosidus will manufacture AVAN’s Peru-15 oral cholera vaccine. Separately, ProdiGene will use its plant transgenic production system to manufacture an undisclosed compound from AVAN. Avant Immunotherapeutics Inc. (AVAN), Needham, Mass.   Biosidus S.A. , Buenos...